Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
Other Sizes |
|
Purity: ≥98%
AZD-0284 is a novel, potent, selective, inverse agonist of the nuclear receptor RORγ. It is in development for the treatment of plaque psoriasis vulgaris and respiratory tract disorders.
ln Vitro |
In human TH17 cells, AZD0284 (0.37 μM; 5 days) suppresses the synthesis of IL-17A [1]. TH17 polarization into pathogenic TH17/1 cells is decreased by AZD0284. Both the frequency of double-positive TH17/1 cells and single IL-17+ cells are decreased by AZD0284. AZD0284 decreases the expression of IL-17A, IL-17F, IL-22, and IL-23R on RNA [1][2].
|
---|---|
References |
|
Molecular Formula |
C21H18F6N2O5S
|
---|---|
Molecular Weight |
524.433445453644
|
Exact Mass |
524.084
|
CAS # |
2101291-07-8
|
PubChem CID |
129205086
|
Appearance |
White to off-white solid powder
|
LogP |
2.3
|
Hydrogen Bond Donor Count |
2
|
Hydrogen Bond Acceptor Count |
11
|
Rotatable Bond Count |
4
|
Heavy Atom Count |
35
|
Complexity |
910
|
Defined Atom Stereocenter Count |
1
|
SMILES |
S(C)(C1C=CC2=C(C=1)CN(C(C)=O)[C@H]2C(NC1C=CC(=CC=1)C(C(F)(F)F)(C(F)(F)F)O)=O)(=O)=O
|
InChi Key |
QYYZXEPEVBXNNA-QGZVFWFLSA-N
|
InChi Code |
InChI=1S/C21H18F6N2O5S/c1-11(30)29-10-12-9-15(35(2,33)34)7-8-16(12)17(29)18(31)28-14-5-3-13(4-6-14)19(32,20(22,23)24)21(25,26)27/h3-9,17,32H,10H2,1-2H3,(H,28,31)/t17-/m1/s1
|
Chemical Name |
(R)-2-acetyl-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-5-(methylsulfonyl)isoindoline-1-carboxamide
|
Synonyms |
AZD-0284; AZD 0284; AZD0284.
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~100 mg/mL (~190.68 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.83 mg/mL (1.58 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.3 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.83 mg/mL (1.58 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.3 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.83 mg/mL (1.58 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.9068 mL | 9.5342 mL | 19.0683 mL | |
5 mM | 0.3814 mL | 1.9068 mL | 3.8137 mL | |
10 mM | 0.1907 mL | 0.9534 mL | 1.9068 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.